FDA Names New Drugs & Labeling Compliance Division Director
This article was originally published in The Pink Sheet Daily
FDA New Drugs & Labeling Compliance Division Acting Director Steven Silverman will assume the role on a permanent basis, FDA announced Feb. 5
You may also be interested in...
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.
Medco, Express Scripts and Cigna maintain that “automated” prior authorization is not feasible because it requires a discussion with the doctor. The PBMs recommend that HHS should support electronic transmission of prior authorization “where feasible.”
Physicians should not have to scroll or click through new windows to see non-preferred and off-formulary drugs, Pfizer, J&J tell the standards subcommittee of the National Committee on Vital & Health Statistics.